Skip to main content

Table 1 Patients’ characteristics according to baseline ALT levels

From: Baseline low ALT activity is associated with increased long-term mortality after COPD exacerbations

 ALT <  11 IU/L11 IU/L ≤ ALT ≤ 40 IU/LP value
Patients’ demographics
 Age (years ± SD)78.8 ± 974.8 ± 11.20.008
 Gender – males (n (%))39 (54.9)77 (47.8)0.32
 Norton score (number, IQR)14.93 (13–17)16.06 (13.5–19)0.002
Background diagnoses (groups)
 Cancer (n (%))20 (28.2)36 (22.4)0.34
 Dementia (n (%))3 (4.2)7 (4.3)0.96
 Diabetes (n (%))33 (46.5)49 (30)0.018
 Cardiovascular (n (%))54 (76.1)119 (73.9)0.73
 Metabolic (n (%))47 (66.2)92 (57.1)0.19
 Neurologic (n (%))17 (23.9)42 (26.1)0.73
 Endocrine (n (%))12 (16.9)21 (13.0)0.49
Medications (groups)
 Steroids (n (%))17 (23.9)28 (17.4)0.24
 Anticoagulation (n (%))27 (38)34 (21.1)0.007
 Inhalers/Inhalation (n (%))46 (64.8)111 (68.9)0.53
 Anti-diabetic (n (%))28 (39.4)48 (29.8)0.15
 Cardiovascular (n (%))62 (87.3)133 (82.6)0.37
 Metabolic (n (%))17 (23.9)33 (20.5)0.56
 Neurologic (n (%))33 (46.5)62 (36.5)0.25
Laboratory parameters
 Albumin (g/dL ± SD)3.4 ± 0.453.7 ± 0.45<  0.001
 Creatinine (mg/dL, (IQR))1.32 (0.93–1.53)1.07 (0.68–1.29)<  0.001
Clinical outcomes
 Mortality (n (%))49 (69.0)55 (34.2)<  0.001
 Survival time – median (months)18.5Median not reached